Results 91 to 100 of about 676,789 (144)

Circulating PD-1⁺ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer. [PDF]

Front Immunol
Wang K, Shao J, Xin K, Zhang L, Liu B, Chen W, Liu Q.   +6 more
europepmc   +1 more source

Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy. [PDF]

Theranostics
Yin JY, Liu HM, Li SL, Ji XQ, Wang JJ, Fu MJ, Liu CJ, Wang N, Lu GL, Li Y, Liu HM, Zheng YC, Dai XJ, Liu Y.   +13 more
europepmc   +1 more source

VSIG2 is associated with an immune-cold microenvironment and reduced response to PD-1 blockade in bladder cancer. [PDF]

Front Cell Infect Microbiol
Wu J, Liang P, He Y, Zhang M, Lin H, Li G, Yu A.   +6 more
europepmc   +1 more source

Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review. [PDF]

Pharmaceutics
Li D, Lu J, Li Q, Deng H, Tan S.
europepmc   +1 more source

Emerging evidence for anti-PD-1 and IFN-γ as adjunctive immunotherapy in invasive mold infections. [PDF]

mBio
Serris A, Guihot A, Joffre J, Dessajan J, Dahuron L, Bosch A, Dudoignon E, Pierot L, Lelièvre L, Lukaszewicz AC, Monneret G, Lambotte O, Martin-Blondel G, Lanternier F.   +13 more
europepmc   +1 more source

The role of tumor metabolic reprogramming in acquired anti-PD-1/PD-L1 resistance. [PDF]

Transl Lung Cancer Res
Gao C, Chen J, Pang B, Su C.
europepmc   +1 more source

Rapid progression to toxic epidermal necrolysis following switch of PD-1 inhibitors: a case report. [PDF]

Front Med (Lausanne)
Huang M, Guan Y, Yang Z.
europepmc   +1 more source

Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective study. [PDF]

Ther Adv Med Oncol
Du Y, Chen Y, Wang J, Lin J, Wei X, Gu J, Guo J, Si L, Mao L.   +8 more
europepmc   +1 more source

CD11c+ CD8 T cells cause IFN-γ-dependent autoimmune neuroinflammation that is restrained by PD-1 signaling. [PDF]

JCI Insight
Hwang D, Azizi G, Ishikawa LLW, Seyedsadr M, Cox A, Jang S, Kasimoglu E, Rostami A, Zhang GX, Ciric B.   +9 more
europepmc   +1 more source

KSR2 functions as a metabolic checkpoint for anti-PD-1 resistance by reprogramming glucose metabolism. [PDF]

Cancer Immunol Immunother
Ge Y, Zhou Q, Zhang Q, Hu Y, Wang R.
europepmc   +1 more source